Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients.

[1]  K. Gaus,et al.  Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages , 2006, Current opinion in lipidology.

[2]  G. Walldius,et al.  The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence , 2006, Journal of internal medicine.

[3]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[4]  F. Cesena,et al.  Comparison of Serum Lipid Values in Patients With Coronary Artery Disease at 70 Years of Age , 2005 .

[5]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[6]  S. Grundy,et al.  Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). , 2005, The American journal of cardiology.

[7]  J. Kastelein,et al.  Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. , 2005, Journal of the American College of Cardiology.

[8]  J. Henning,et al.  Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? , 2004, American heart journal.

[9]  M. Connelly,et al.  Scavenger Receptor Class B Type I-mediated Cholesteryl Ester-selective Uptake and Efflux of Unesterified Cholesterol , 2004, Journal of Biological Chemistry.

[10]  G. Franceschini,et al.  Depletion of Pre-β-high Density Lipoprotein by Human Chymase Impairs ATP-binding Cassette Transporter A1- but Not Scavenger Receptor Class B Type I-mediated Lipid Efflux to High Density Lipoprotein* , 2004, Journal of Biological Chemistry.

[11]  G. Franceschini,et al.  An ω-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia , 2004 .

[12]  A. Zwinderman,et al.  Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS) , 2004, European journal of clinical investigation.

[13]  P. Yancey,et al.  Importance of different pathways of cellular cholesterol efflux. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[14]  James W. Anderson,et al.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). , 2002, Archives of internal medicine.

[15]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[16]  W. Fung-Leung,et al.  Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Ballantyne,et al.  Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S , 2001, Circulation.

[18]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[19]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[20]  T. Miida,et al.  Bezafibrate Increases Pre&bgr;1-HDL at the Expense of HDL2b in Hypertriglyceridemia , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[21]  J. Marrugat,et al.  Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[23]  M. Rieser,et al.  Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers , 2000, Journal of clinical pharmacology.

[24]  A. Hamsten,et al.  Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). , 1998, Journal of the American College of Cardiology.

[25]  A Pasternack,et al.  Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. , 1998, Circulation.

[26]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[27]  G. Franceschini,et al.  Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Y. Marcel,et al.  Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[29]  E. Bruckert,et al.  Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[30]  G. Franceschini,et al.  Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[31]  H. Yamaguchi,et al.  Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. , 1995, Atherosclerosis.

[32]  L. Labree,et al.  Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[33]  V. Vaccarino,et al.  Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. , 1989, The Journal of laboratory and clinical medicine.

[34]  A. Gotto,et al.  Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. , 1984, The Journal of clinical investigation.

[35]  G. Luc,et al.  Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia , 2004, European Journal of Clinical Pharmacology.

[36]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[37]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[38]  M. Farnier,et al.  Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. , 2000, Arteriosclerosis, thrombosis, and vascular biology.